Industries > Pharma > Gene Therapy R&D Market Report 2021-2031

Gene Therapy R&D Market Report 2021-2031

Forecasts by Disease (Cancer, Rare Diseases (Oncologic, Non-Oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Hematology, Neurological, Diabetes Mellitus, Other Diseases), by Vector (Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-Viral (Naked DNA, Gene Gun, Electroporation, Lipofection)), by Techniques (Gene Augmentation Therapy, Gene Replacement Therapy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Gene Therapy Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 11 June 2021
PAGES: 475
PRODUCT CODE: PHA1136

Clear
WOOCS 2.2.1

Gene Therapy R&D Market– Our new study reveals trends, R&D progress, and predicted revenues over the next decade

Facility Expansion Anticipated to Offer Lucrative Growth Prospects
The rise in clinical-stage start-ups has resulted in a shortage of viral vector manufacturing capacity among contract manufacturers, which new gene & cell therapy companies rely on for early-stage development. As these businesses grow to commercial size, they often tend to have complete control over their manufacturing to avoid the complications of outsourcing. As a result, biotech companies started to develop growth strategies, organize internal teams, and/or seek site consultant advice.

Gene Therapies to Offer Promising Results for Patients Over the Next Decade
Gene therapies are among the most complicated medical treatments ever invented. They are producing promising results for patients because they are precisely programmed to replace faulty genes or reprogram and redirect immune cells against cancer. Children who are experiencing vision loss that may lead to blindness will be able to change their course. Cancer patients who have exhausted all other choices may be able to reclaim their lives. Although the possibilities provided by gene therapy seem endless, more work remains to be done to tackle more diseases and increase the number of patients that can be treated and cured using these amazing medicines.

Which Factors Are Driving the Growth of Gene Therapy R&D Market?
• Robust Gene Therapy Pipeline to Boost Growth
• Increasing Investments by Major Players to Augur Market Growth
• Growing Prevalence of Targeted Diseases Treatment
• Technological Advancements to Fuel Market Growth

What are the Opportunities for Gene Therapy R&D Market Players?
• Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
• Facility Expansion Anticipated to Offer Lucrative Growth Prospects

How are prominent players reinforcing their position across the global business?
Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies. See where the expected gains will be. View Visiongain’s assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of leading companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and outlook.

Discover how to stay ahead
Our 470+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Gene Therapy R&D Market. See how to exploit the opportunities.

To access the data contained in this document please email contactus@visiongain.com

CTA

Gene Therapy R&D Market Segmentation

Disease
• Cancer
• Rare Diseases: Oncologic, Non-Oncologic
• Cardiovascular Diseases
• Ophthalmic Diseases
• Hematology
• Neurological
• Diabetes Mellitus
• Other Diseases

Vector

• Viral
– Retrovirus
– Adenovirus
– AAV
– Lentivirus
– Others

• Non-Viral
– Naked DNA
– Gene Gun
– Electroporation
– Lipofection

Techniques
• Gene Augmentation Therapy
• Gene Replacement Therapy

By Region

• North America
– U.S.
– Canada

• Europe
– Germany
– UK
– France
– Italy
– Spain
– Russia
– Rest of Europe

• Asia Pacific
– China
– Japan
– India
– Australia
– Rest of Asia Pacific

• Latin America
– Brazil
– Mexico
– Rest of Latin America

• Middle East & Africa
– GCC
– South Africa
– Rest of Middle East & Africa

Gene Therapy R&D Market Report 2021-2031
Need industry data? Please contact us today.

COVID-19 Impact Recovery Scenarios
This report includes Baseline Forecasts along with Different Rebound Scenarios to help analyze the global Gene Therapy R&D market-no matter how COVID-19 affects the economy.

To access the data contained in this document please email contactus@visiongain.com

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.

Leading countries and the potential for market growth
Overall world revenue for Gene Therapy R&D market will surpass US$xx in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Gene Therapy R&D Market report helps you
In summary, our 480+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Gene Therapy R&D Market, with forecasts for production process, application, product, and material, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 16 key national markets– See forecasts for the Gene Therapy R&D market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Also forecasted is the market in the US, Canada, Germany, UK, France, Italy, Russia, Japan, China, India, Australia, Brazil, Mexico, GCC, and South Africa among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 16 of the major companies involved in the Gene Therapy R&D Market. Some of the companies profiled in this report are UniQure B. V., Biogen, Bluebird Bio, Spark Therapeutics (Subsidiary of Roche), Bayer, Pfizer, Inc., Applied Genetic, Oxford Biomedica, GenSight Biologics, Takeda Pharmaceuticals, Cellectis, Sangamo Therapeutics, Inc., REGENXBIO Inc., Voyager Therapeutics, Bristol Myers Squibb, Benitec BioPharma, F. Hoffmann-La Roche Ltd., Novartis AG, Gilead Lifesciences, Inc., Sanofi, Transgene, Calimmune, Inc. (CSL Behiring), Astellas Pharma Inc., American Gene Technologies, and Orchard Therapeutics among other prominent players.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Gene Therapy R&D Market and leading companies. You will find data, trends, and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Gene Therapy R&D Market Report 2021-2031: Forecasts by Disease (Cancer, Rare Diseases (Oncologic, Non-Oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Hematology, Neurological, Diabetes Mellitus, Other Diseases), by Vector (Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-Viral (Naked DNA, Gene Gun, Electroporation, Lipofection)), by Techniques (Gene Augmentation Therapy, Gene Replacement Therapy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Gene Therapy Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Gene Therapy R&D Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Gene Therapy R&D Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories